Meta-analysis of the effect of Qiliqiangxin capsules for patients with heart failure and preserved ejection fraction
XU Qiang
LIU Hongjun
LIU Xuehui
Abstract：Objective To systemic evaluate the effect of Qiliqiangxin capsules in the treatment of heart failure with preserved ejection fraction (HFpEF).Methods Systemic retrieval CNKI, Wanfang medicine and VIP database from data-base self-building to March 1, 2015, collected randomized controlled trials (RCT) of Qiliqiangxin capsules in the treatment of HFpEF.Statistical analysis were performed using 5.2.0 RevMan software.Results A total of 10 articles (829 cases) were included.Meta-analysis showed that, on the basis of routine treatment, the Qiliqiangxin capsules can help to further improve the cardiac function (RR=1.41, 95%CI 1.15 to 1.71, P <0.01), E/a value (WMD=0.14, 95% CI 0.07 to 0.21, P <0.01), and 6 min walking distance (WMD=67.40, 95%CI 2.17 to 132.63, P =0.04), also reduced the brain natri-uretic peptide (WMD=-93.46, 95%CI -121.98 to -64.93, P <0.01) and N-terminal pro brain natriuretic peptide (WMD=-543.45, 95%CI -924.25 to -162.65, P <0.01) level.Conclusion Qiliqiangxin capsules has good cura-tive effect in the treatment of HFpEF wiht high safety , which is worthy of promotion .
Keywords：Qiliqiangxin capsulesHeart failure with preserved ejection fractionMeta-analysis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 898-901 )